An official website of the United States government
Cohort profile: The MULTI sTUdy Diabetes rEsearch (MULTITUDE) consortium.
Pubmed ID: 29730626
Pubmed Central ID: PMC5942412
Journal: BMJ open
Publication Date: May 5, 2018
MeSH Terms: Humans, Male, Adult, Female, Aged, Aged, 80 and over, Risk Factors, United States, Cohort Studies, Adolescent, Middle Aged, Smoking, Prevalence, Chronic Disease, Young Adult, Child, Comorbidity, Incidence, Obesity, Databases, Factual, Diabetes Mellitus, Type 2, Demography, Research Design, Child, Preschool
Grants: P30 DK046200, K12 HD000849
Authors: Moore LL, Vasan RS, Kalesan B, Li F, Pino EC, Zuo Y, Maciel De Olivera C, Mahalingaiah S, Keiser O, Corkey BE
Cite As: Pino EC, Zuo Y, Maciel De Olivera C, Mahalingaiah S, Keiser O, Moore LL, Li F, Vasan RS, Corkey BE, Kalesan B. Cohort profile: The MULTI sTUdy Diabetes rEsearch (MULTITUDE) consortium. BMJ Open 2018 May 5;8(5):e020640.
Studies:
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)
- Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
- Atherosclerosis Risk in Communities Study (ARIC)
- Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM)
- Bogalusa Heart Study (BHS)
- Bypass Angioplasty Revascularization Investigation (BARI)
- Cardiovascular Cell Therapy Research Network (CCTRN) Randomized, Controlled, Phase II, Double-Blind Trial of Intramyocardial Injection of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Patients With Chronic Ischemic Heart Disease and Left Ventricular Dysfunction (FOCUS)
- Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
- Framingham Heart Study (FHS) Offspring (OS) and OMNI 1 Cohorts
- Framingham Heart Study (FHS) Third Generation (Gen III), OMNI 2, and New Offspring (NOS) Cohorts
- Framingham Heart Study-Cohort (FHS-Cohort)
- Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)
- NHLBI Growth and Health Study (NGHS)
- Optimal Macronutrient Intake Trial to Prevent Heart Disease (OMNI Heart)
- Practice Based Opportunities for Weight Reduction Trial at the University of Pennsylvania (POWER-UP)
- Systolic Blood Pressure Intervention Trial Primary Outcome Paper (SPRINT-POP) Data
- The Jackson Heart Study (JHS)
Abstract
PURPOSE: Globally, the age-standardised prevalence of type 2 diabetes mellitus (T2DM) has nearly doubled from 1980 to 2014, rising from 4.7% to 8.5% with an estimated 422 million adults living with the chronic disease. The MULTI sTUdy Diabetes rEsearch (MULTITUDE) consortium was recently established to harmonise data from 17 independent cohort studies and clinical trials and to facilitate a better understanding of the determinants, risk factors and outcomes associated with T2DM. PARTICIPANTS: Participants range in age from 3 to 88 years at baseline, including both individuals with and without T2DM. MULTITUDE is an individual-level pooled database of demographics, comorbidities, relevant medications, clinical laboratory values, cardiac health measures, and T2DM-associated events and outcomes across 45 US states and the District of Columbia. FINDINGS TO DATE: Among the 135 156 ongoing participants included in the consortium, almost 25% (33 421) were diagnosed with T2DM at baseline. The average age of the participants was 54.3, while the average age of participants with diabetes was 64.2. Men (55.3%) and women (44.6%) were almost equally represented across the consortium. Non-whites accounted for 31.6% of the total participants and 40% of those diagnosed with T2DM. Fewer individuals with diabetes reported being regular smokers than their non-diabetic counterparts (40.3% vs 47.4%). Over 85% of those with diabetes were reported as either overweight or obese at baseline, compared with 60.7% of those without T2DM. We observed differences in all-cause mortality, overall and by T2DM status, between cohorts. FUTURE PLANS: Given the wide variation in demographics and all-cause mortality in the cohorts, MULTITUDE consortium will be a unique resource for conducting research to determine: differences in the incidence and progression of T2DM; sequence of events or biomarkers prior to T2DM diagnosis; disease progression from T2DM to disease-related outcomes, complications and premature mortality; and to assess race/ethnicity differences in the above associations.